Pharmacogenetics: LabQuality Days Helsinki, February 8, Do you have your DNA passport? Prof Dr Ron van Schaik
|
|
- Monica Black
- 6 years ago
- Views:
Transcription
1 LabQuality Days Helsinki, February 8, 2018 Pharmacogenetics: Do you have your DNA passport? Prof Dr Ron van Schaik International Expert Center Pharmacogenetics Dept Clinical Chemistry - Erasmus MC Rotterdam, The Netherlands
2 Professor Pharmacogenetics Clinical Chemist (EuSpLM) Dept.Clinical Chemistry, Erasmus MC Rotterdam Director International Referencecenter Pharmacogenetics (IFCC) European Pharmaco- Genetics Implementation Consortium (chair) European Society for Pharmacogenomics & Personalized Therapy (President) PGx Working Group Personalized Med. Div. Mol Diagnostics Comm. Task Force PGx (chair) PGx Committe (chair) Dutch clinical PGx Network (chair) Mol Diagnostics Comm. (chair) Scientific board Dutch PGx Working Group
3 Pharmacogenetics DNA analysis to explain/ to predict the response of a patient to drug therapy Personalized Medicine Precision Medicine
4 Metabolism of drugs Blood Blood Cytochrome P450 enzymes Liver
5 Metabolism of drugs Drug concentration in blood Intestinal uptake Interindividual variation in drug metabolism Metabolism by the liver Slow metabolism Ultra-Rapid metabolism ADVERSE DRUG REACTIONS 5-7% of all hospitalizations is are due to Adverse Drug Reactions (Lazarou 1998). ADRs are the 5th cause of death. Therapeutic window Only 25-60% of all drugs prove to be effective in treatment SUBTHERAPEUTIC Dose Time Dose
6 CYTOCHROME P450 ENZYMES
7 Cytochrome P450 enzymes: 80% of all drugs ( Anti-depressives Clopidogrel (Plavix) Proton Pump Inhibitors CYP2C19 8% Efavirenz CYP2B6 CYP2E1 3% 4% CYP2A6 3% Oncology drugs Psychiatric drugs Cyclosporin, CYP3A4 tacrolimus & many, 36% many more Clozapine CYP1A2 11% CYP2D6 19% CYP3A % CYP2C9 16% Anti-coagulation (warfarin, acenocoumarol) CYP2D6 20% Anti-depressives Antipsychotics Beta-blockers Tamoxifen
8 CYP2D6 activity in Caucasian population Normal % Percentage of individual Ultra-rapid ~ 2-5 % Intermediate ~10-15 % Slow 5-10 % MR S CYP2D6 enzyme activity (metabolic ratio: debrisoquine 4OH debrisoquine)
9 CYP2D6 variant alleles in Caucasians: *1-*105
10 Geographic distribution of CYP2D6 gene duplication 1-2% 3.6% 7-10% 10% 20% 29%
11 Drugs that are substrate for CYP2D6 Pain codeine dextrometorfan dihydrocodeine ethylmorphine hydrocodone norcodeine oxycodone tramadol ADHD Atomoxetine (Staterra) Anti-arrhytmics aprindine encainide flecainide mexiletine N-propylajmaline procainamide propafenone sparteine Anti-dementia galanthamine nicergoline Anti-depressives amitryptyline clomipramine desipramine imipramine nortryptiline citalopram desmethylcitalopram fluoxetine fluvoxamine maprotiline mianserin minaprine mirtazapine paroxetine venlafaxine Antidiabetics fenformine Anti-estrogens tamoxifen Antihypertensives debisoquine guanoxan indoramin Anti-emetics dolasetron ondansetron tropisetron Anti-histaminics mequitazine promethazine Appetite inhibitors dexfenfluramine Antipsychotics haloperidol perphenazine risperidon thioridazine zuclopenthixol See also: ß - blockers alprenolol bufuralol bunitrolol bupranolol carvedilol metoprolol propanolol timolol Ca-antagonists perhexiline MAO inhibitors amiflamine brofaromine Drugs methoxyamfetamine MDMA, MDME cinnarizine flunarizine (Zanger et al 2003)
12 Clinical aplication Psychiatry Antidepressants & CYP2D6
13 Imipramine therapy (antidepressive) Hospitalization Start therapy 1st conc 2nd conc 3rd conc 4th conc 1 week 1 week 1 week 1 week 1 week 22:00 ~ 50% patients: dose adjustment based on drug concentration in blood Time in academic hospital: 4-6 weeks
14 IMI dose (mg/day) Imipramine dosis (mg/dag) Imipramine metabolism Paul Schenk et al 2008 Mol Psychiatry 0 n=11 n=69 n=90 n=11 CYP2C19 CYP2D6 Imipramine Desipramine 2OH-desipramine Imipramine dosis na bereiken van stabiele therapie 25% of standard dose >2 CYP2D6 SGD Active copies of CYP2D6
15 Stingl et al Mol Psychiatry 2013
16 Case Genotype: CYP2D6*1/*1xN > 3 alleles Ultrarapid Metabolizer A 63 year old male was prescibed nortiptylene in our Academic Center after no effect on several SSRIs. Again, no effect was seen of nortiptylene and plasma concentrations that were determined were low. The psychiatrist considered two options: Nortiptylene CYP2D6 a) noncompliance b) CYP2D6 ultrarapid metabolism
17 Case 2 (May 2015) A 26 year old woman has been suffering from depression since childhood. She has been treated with several antidepressants, but all leading to severe side effects. Now she is on fluoxetine, again with side effects, for which she receives additional medication Treatment Dosing Effect Action Paroxetine Standard Many side effects Stopped Clomipramine 150 mg Side effects / High plasma concentrations Stopped Nortriptyline Standard High plasma concentrations Stopped Risperidon Low Extrapyrimidal side effects Stopped Fluoxetine mg/day Side effects (itch, obsitipation, dry eyes) Antihistaminics, laxantia and eye-dropps Genotype: CYP2D6*4/*4 2 defective alleles Poor Metabolizer
18 Genotype vs non-genotype guided treatment of depression DNA Conventional guided (Hall Flavin 2013 Pharmacogenomics)
19 Clinical aplication Cardiology Metoprolol & CYP2D6
20 CYP2D6 and metoprolol Dosing Guidelines: PM: 25% of standard dose IM: 50% of standard dose UM: 250% of standard dose S-metoprolol plasma concentration (ng/ml) ( CYP2D6: EM IM PM 0
21 Clinical aplication Oncology Tamoxifen & CYP2D6
22 Breast cancer and Tamoxifen TAMOXIFEN Effective metabolite
23 CYP2D6 and disease free survival on tamoxifen Disease free period Proportion of patients 20% Normal Intermediate Slow Clin Pharmacol Ther 2018 Time (years) (Schroth et al 2009 JAMA)
24 Clinical aplication Pain Opiods & CYP2D6
25 Codeine Tramadol Codeine X CYP2D6 Morphine No pain relief UGT2B7 Morphine-glucuronide
26 Codeine Codeine Morphine Morphine CYP2D6 UGT2B7 Morphine-glucuronide
27 CYP2D6 UM
28 >160 drugs now with PGx info in the drug label
29 Where could PGx help you? % of population with variant alleles Psychiatry: Antidepressants, antipsychotics CYP2D6, 2C19, 1A2, 3A4 10% Cardiology: Clopidogrel (Plavix) CYPC19 15% Statins SLCO1B1 2% Warfarin /acenocoumarol CYP2C9, VKORC1 20% Oncology: Tamoxifen (breast) CYP2D6 10% Capecitabine / 5-FU DPYD 2% 6-mercaptopurine (ALL) TPMT 11% Irinotecan (colon) UGT1A1 15% Neurology Phenytoin CYP2C9, 2C19 20% Clobazam CYP3A4, 2C19 20% Dermatology Azathioprine TPMT 11% Pain Codeine, tramadol, oxycodon CYP2D6, OPRM1, COMT 10% Internal Medicine Azathioprine (Crohn s disease) TPMT 11% HIV Efavirenz CYP2B6 5% Abacavir HLA-B*5701 4% Organ Tx Azathioprine TPMT 11% Tacrolimus/cyclosporin CYP3A5, 3A4 20% MMF UGT1A9 12%
30 The laboratory Pharmacogenetics for improving patient care:
31 HLA-B*1502
32 Erasmus MC 2 independent platforms (of which is 1 CE-IVD) TAT 3 5 days In collaboration with hospital pharmacy/ clinical pharmaclogy CE-IVD test
33 Special considerations on quality for PGx testing? 1. 1 ml of blood is stored for allowing redoing DNA extraction and DNA analysis 2. DNA analysis is done with two different platforms (allele drop out!)
34 Allele drop out No mutation Primer 1 No mutation Primer 1 Primer 2 x Primer 2 Primer 1 Mutation x Primer 2 Primer 1 Mutation x Primer 2 Outcome: heterozygous Outcome: homozygous mutant
35 HOW SERIOUS A PROBLEM IS THIS?
36
37 Fluoropyrimidines and DPD Capecitabine Fluoropyrimidines: 5-fluorouracil (5-FU) and capecitabine Widely used (e.g. colorectal cancer, breast cancer) ~10-30% of patients develop severe (grade 3) toxicity Diarrhea, mucositis, hand-foot-syndrome 5-FU 10-20% Excretion (urine) This results in hospitalization or suboptimal treatment ~1% of patients develop fatal toxicity >80% DPD 1-5% Dihydropyrimidine dehydrogenase (DPD) DPD plays a key role in fluoropyrimidine metabolism DPD deficiency occurs in 3-5% of the population Associated with increased risk of severe/fatal toxicity Upfront screening and dose individualization can improve patient safety DHFU (inactive) Cytotoxicity: DNA incorporation and damage Active metabolites Toxicity (slide courtesy of Linda Henricks - NKI)
38 PROSPECTIVE STUDY DPYD*2A genotype-guided dosing of fluoropyrimidines Deenen et al. J Clin Oncol 2016 (slide Linda Henricks) SYSTEMATIC REVIEW OF THE LITERATURE Patients who have DPYD*2A variant (heterozygous) N = 48 73% Patients screened for DPYD*2A variant n = 2035 (1631 treated) Patients who have DPYD*2A variant (heterozygous) N = 18 (1.1%) Patients without DPYD*2A variant N = 1613 (99%) Treated with full dose 50% dose reduction of 5-FU / capecitabine 28% Treated with normal dose (standard of of care) 23% P = P =
39 Here is my sequence (The New Yorker, 2000) Dutch Pharmacy PGx working group: Evidence-based dosing guidelines per genotype for > 60 drugs Rating evidence: Rating Clinical effect: 1 4 (RCT) A - F (death)
40 Here is my sequence (The New Yorker, 2000)
41
42
43 Make sure you know if your patient can handle the drug you prescribe! Wishing you safe genotyping
Ron van Schaik. Pharmacogenetics. London, Oct 8-9, Clinical implementation: a 7 year experience
Ron van Schaik Associate Professor Pharmacogenetics Eur Clin Chem / Advisor EMA - PGWG London, Oct 8-9, 2012 Pharmacogenetics Clinical implementation: a 7 year experience Pharmacogenetics Core Laboratory*
More informationPharmacogenetics: DNA analysis. to explain / predict. response to drug therapy. Maurizio Ferrari & Ron van Schaik
Maurizio Ferrari & Ron van Schaik Workshop IFCC Kuala Lumpur November 19, 2012 Predictive, Preventive and Personalized Medicine Part II: Pharmacogenetics l r.vanschaik@erasmusmc.nl Pharmacogenetics: DNA
More informationTwo decades of clinical pharmacogenetic testing - Where do we stand?
Two decades of clinical pharmacogenetic testing - Where do we stand? Marja-Liisa Dahl, MD PhD, Professor Dept of Clinical Pharmacology Karolinska University Hospital/Karolinska Institutet Stockholm, Sweden
More informationImipramine therapy (CYP2D6)
Imipramine therapy (CYP2D6) Intake Start therapy 1st conc 08:00 2nd conc 3e spiegel 4e spiegel 1 week 1 week 1 week 1 week 1 week 22:00 ~ 50% patients need dose adjustment Imipramine therapy (CYP2D6) Intake
More informationGuidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence
Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole
More informationAre health care systems ready to deliver pharmacogenetics as standard of care? Predicting the needs and setting the strategies
Are health care systems ready to deliver pharmacogenetics as standard of care? Predicting the needs and setting the strategies David Gurwitz Sackler Faculty of Medicine, Tel-Aviv University, Israel OECD,
More informationPsychotropic & Unnecessary Medication Reduction: Living Longer Better : Utilizing The Clinical Tool of Metabolic Validation Testing
Psychotropic & Unnecessary Medication Reduction: Living Longer Better : Utilizing The Clinical Tool of Metabolic Validation Testing CMS NEWEST GUIDELINES CMS will push nursing homes to reduce their use
More informationPharmacogenetics: From Bench to Byte An Update of Guidelines
nature publishing group Pharmacogenetics: From Bench to Byte An Update of Guidelines JJ Swen 1, M Nijenhuis 2, A de Boer 3, L Grandia 2, AH Maitland-van der Zee 3, H Mulder 3,4, GAPJM Rongen 5,6,7, RHN
More informationMental Health DNA Insight WHITE PAPER
Mental Health DNA Insight WHITE PAPER JULY 2016 Mental Health DNA Insight / White Paper Mental Health DNA Insight Pathway Genomics Mental Health DNA Insight test is aimed to help psychiatrists, neurologists,
More information6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES
6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES Ron H.N. van Schaik Dept. Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands 6.1 Introduction In today s medicine, drug therapy represents
More informationReview of Pharmacogenetic Testing Today
Review of Pharmacogenetic Testing Today Gwen McMillin, PhD ARUP Laboratories University of Utah Salt Lake City, Utah A customer says to the pharmacist: "Why does my medication have 40 side effects?" The
More informationPharmacogenomics of Medications for Pain and Major Depression: Promise and Peril
Pharmacogenomics of Medications for Pain and Major Depression: Promise and Peril Geoffrey C. Wall, PharmD, FCCP, BCPS, CGP Professor of Clinical Sciences Drake University College of Pharmacy and Health
More informationHow to use pharmacogenetics to select patients for pharmaceutical care
How to use pharmacogenetics to select patients for pharmaceutical care Prof. Henk-Jan Guchelaar Dept. of Clinical Pharmacy & Toxicology Leiden University Medical Center University of Leiden PCNE Working
More informationPharmacogenomics and Clinical Practice: Ready for Prime Time? Disclosures. Elder-Friendly Futures Conference 2013 A UW Gerontology Conference
Pharmacogenomics and Clinical Practice: Ready for Prime Time? Manju T. Beier, Pharm D, CGP, FASCP Chief Scientific Officer Natural Molecular Testing Corp. Adjunct Clinical Associate Professor of Pharmacy
More informationPharmacogenetic Testing in Psychiatry Jose de Leon, MD ( )
Pharmacogenetic Testing in Psychiatry Jose de Leon, MD (12-01-15) Conflicts of Interest (See more details on conflict of interest in the first presentation Training Psychiatrists to Think like Pharmacologists
More information3. Describe how variants in the CYP2C19 gene impact Plavix metabolism. 4. Compare molecular genetic technologies for pharmacogenomics testing
UP! UNDERSTANDING PHARMACOGENOMICS (PGX) Robert Pyatt Ph.D., Director Sanford Medical Genetics and Genomics Laboratories and Associate Professor, Dept of Internal Medicine, University of South Dakota April
More informationImplementing Pharmacogenetic Testing Into Clinical Laboratories. Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories
Implementing Pharmacogenetic Testing Into Clinical Laboratories Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories Key learning objectives Recognize decisions in implementing pharmacogenetic
More informationGenetic Screening for ADR
Genetic Screening for ADR Mahidol University Faculty of Medicine Siriraj Hospital Manop Pithukpakorn, MD Division of Medical Genetics Department of Medicine concentration Drug level over time toxic optimum
More informationPharmacogenomics In Psychiatry. Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University. XGEN Group NIH PGRN
Pharmacogenomics In Psychiatry Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University XGEN Group NIH PGRN Why do we need biomarkers in drug therapy? Limited efficacy Adverse drug effects
More informationPharmacogenomics Gene/Drug-Pair Decision Flow Charts 2017
Pharmacogenomics Gene/Drug-Pair Decision Flow Charts 2017 Atomoxetine Prescription CYP2D6 Genotype (AS = 0) (AS = 0.5 1.0) (As = 2.0) Ultrarapid (AS >2.0) Standard dose. Dose increase probably not necessary;
More informationArticle. Reference. Applications of CYP450 Testing in the Clinical Setting. SAMER, Caroline Flora, et al.
Article Applications of CYP450 Testing in the Clinical Setting SAMER, Caroline Flora, et al. Abstract Interindividual variability in drug response is a major clinical problem. Polymedication and genetic
More informationImplémentation clinique de la pharmacogénétique
Implémentation clinique de la pharmacogénétique Vincent HAUFROID Cliniques Universitaires St Luc Université catholique de Louvain Louvain centre for Toxicology and Applied Pharmacology (LTAP) Pharmacogenetics:
More informationPharmacogenomics and Clinical Practice: Ready for Prime Time?
Pharmacogenomics and Clinical Practice: Ready for Prime Time? Manju T. Beier, Pharm D, CGP, FASCP Chief Scientific Officer Natural Molecular Testing Corp. Adjunct Clinical Associate Professor of Pharmacy
More informationMembership Overview: Total Members: 322 Student Members: 160 Resident Members: 8 Fellow Members: 4
A Closer Look at the Central Nervous System PRN Overview of the PRN The Central Nervous System Practice and Research Network (CNS PRN) provides a forum to encourage networking among pharmacists specializing
More informationVariability Due to Genetic Differences
1 Variability Due to Genetic Differences Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland 2 Objectives Understand how between individual variation may contribute to :» drug
More informationCORE DME PANEL Highlands Parkway, Suite 100 Smyrna, GA 30082
CORE DME PANEL Castle's CORE DME panel predicts the activity levels of key - drug metabolizing enzymes in the cytochrome P450 superfamily: CYP2D6, CYP2C9, CYP2C19, CYP2B6, CYP3A4, and - CYP3A5. Apart from
More informationObjectives. Clinical Problem. What if there were a way. Pharmacogenomics in Current Practice MEDICINE 12/1/2017
Objectives Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Review the concept of pharmacogenetics and pharmacogenomics
More informationPharmacogenomics in Current Practice. Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy.
Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Objectives Review the concept of pharmacogenetics and pharmacogenomics
More informationPharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA
Pharmacogenetics of Codeine Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA 1 Codeine Overview Naturally occurring opium alkaloid Demethylated to morphine for analgesic effect
More informationSAMPLE REPORT MENTAL HEALTH DNA INSIGHT LABORATORY INFO. Protected Health Information. SSRIs. TCAs. Other Antidepressants
Test Results Reviewed & Approved by: Laboratory Director, Nilesh Dharajiya,.D. ENTAL HEALTH DNA INSIGHT PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROFESSIONAL Glenn Braunstein.D.
More informationPrecision Medicine Under the Big Sky
Precision Medicine Under the Big Sky Erica L. Woodahl, Ph.D. Associate Professor Department of Biomedical and Pharmaceutical Sciences University of Montana Disclosure Statement Presenter has no financial
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Cytochrome p450 Genotyping Page 1 of 24 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: See Also: Cytochrome p450 Genotyping Genetic Testing for Helicobacter
More informationPersonalized Prescribing: Using Genetic Testing to Guide Drug and Dose Selection. Lindsay S. Elliott, Pharm.D., CGP
Personalized Prescribing: Using Genetic Testing to Guide Drug and Dose Selection Lindsay S. Elliott, Pharm.D., CGP Disclosure I, Lindsay Elliott, am a pharmacy consultant for Genelex Corporation in conducting
More informationPharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
(2004) 9, 442 473 & 2004 Nature Publishing Group All rights reserved 1359-4184/04 $25.00 www.nature.com/mp FEATURE REVIEW Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic
More informationGenetics and Genomics: Influence on Individualization of Medication Regimes
Genetics and Genomics: Influence on Individualization of Medication Regimes Joseph S Bertino Jr., Pharm.D., FCCP Schenectady, NY USA Goals and Objectives To discuss pharmacogenetics and pharmacogenomics
More informationDihydropyrimidine Dehydrogenase (DPYD) Pharmacogenetic Competency
Dihydropyrimidine Dehydrogenase (DPYD) Pharmacogenetic Competency Updated on 6/2015 Pre-test Question # 1 A patient has a reported pharmacogenetic test result of DPYD *1/*2. What is the assigned phenotype?
More informationPharmacogenetics Implementation at Cincinnati Children s Hospital Medical Center (CCHMC)
Pharmacogenetics Implementation at Cincinnati Children s Hospital Medical Center (CCHMC) Laura Ramsey, PhD Co-Director, Genetic Pharmacology Service Assistant Professor Divisions of Research in Patient
More informationClinical Implementation of Pharmacogenetics Mary V. Relling, Pharm.D.
Clinical Implementation of Pharmacogenetics Mary V. Relling, Pharm.D. Actionable pharmacogenetic gene/drug pairs have been known for a long time Primaquine G6PD Codeine CYP2D6 Thiopurines TPMT 5FU DPYD
More informationIs Your Prescription Medication Working Properly for You?
Is Your Prescription Medication Working Properly for You? The traditional approach of prescribing medication is through the trial and error method using the assumption that one size fits all. With pharmacogenetic
More informationThey deserve personalized treatment
Your patients are unique They deserve personalized treatment New laboratory service offered by STA 2 R is a panel of genetic tests that gives prescribers answers to the clinical questions below. The test
More informationDeliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing
GA N 668353 H2020 Research and Innovation Deliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing WP N and Title: WP2 - Towards shared European Guidelines for PGx Lead beneficiary:
More informationGeneDose Genetic Response Report
ISPM Labs d/b/a Capstone Diagnostics 8601 Dunwoody Pl, Ste 444 Atlanta GA 30350 Phone: (678) 515-4524 Fax: (470) 355-5462 Laboratory Director: John Hanson, PhD CLIA ID Number: 11D2073885 http://www.capstonediagnostics.com
More informationPharmacogenomics and Pharmacokinetics ^
Pharmacogenomics and Pharmacokinetics ^ avid F. Kisor, B.S., Pharm.. Profeor of Pharmacokinetics epartment of Pharmaceutical and Biomedical Sciences Raabe College of Pharmacy Ohio Northern University Learning
More informationGenomics (HMGP 7620) Pharmacogenomics.
Genomics (HMGP 7620) Pharmacogenomics http://unlockinglifescode.org/explore/genomic-medicine/pharmacogenomics Matthew Taylor MD PhD matthew.taylor@ucdenver.edu Variety is the Spice of Life Current Model:
More informationCardiovascular pharmacogenomics: ready for prime time?
Cardiovascular pharmacogenomics: ready for prime time? Simon de Denus, pharmacist, MSc (Pharm), PhD Université de Montréal Beaulieu-Saucier Chair in Pharmacogenomics Assistant professor, Faculty of Pharmacy,
More informationQuetiapine Case 1 Warfarin Jose de Leon, MD
Quetiapine Case 1 Warfarin 1-23-16 Jose de Leon, MD 1. Quetiapine Case 1 J Clin Psychopharm 1999;19:382-3 http://www.ncbi.nlm.nih.gov/pubmed/10440472 Educational Objectives At the conclusion of this presentation,
More informationRisperidone Case 1: Drug-Drug Interactions
Risperidone Case 1: Drug-Drug Interactions 1-14-16 de Leon & Bork (a resident) J Clin Psychiatry 1997;58:450-1 http://www.ncbi.nlm.nih.gov/pubmed/9375597 Jose de Leon, MD Educational Objectives At the
More informationPediatric Pharmacogenetic Genotyping Panel
Pediatric Pharmacogenetic Genotyping Panel Table of Contents ABOUT THE TEST... 2 INDICATIONS... 2 TURNAROUND TIME... 2 MEDICATION LIST... 4 About the test Pharmacogenetics is the study of genetic determinants
More informationCytochrome p450 Genotyping. Description. Section: Medicine Effective Date: July 15, 2015
2.04.38 Subject: Cytochrome p450 Genotyping Page: 1 of 30 Last Review Status/Date: June 2015 Cytochrome p450 Genotyping Description The cytochrome p450 (CYP450) family is involved in the metabolism of
More informationYes if indicated below. (4.0 TMPT does not require prior authorization)
Genetic Testing for Pharmacogenetics MP9479 Covered Service: Prior Authorization Required: Additional Information: Medicare Policy: BadgerCare Plus Policy: Yes when meets criteria below Yes if indicated
More informationSelf Assessment Question 1
Drug Interactions Bruce G. Pollock, M.D., Ph.D. Professor of Psychiatry, Pharmacology and Nursing Chief, Academic Division of Geriatrics and Neuropsychiatry University of Pittsburgh Medical Center 1 Self
More informationPsychiatric Pharmacogenomics: Introduction and Applications
Psychiatric Pharmacogenomics: Introduction and Applications Moises Gaviria, MD Distinguished Professor of Psychiatry University of Illinois at Chicago Medical Director The Institute of Neurobehavioral
More informationPharmacogenetics in: Primary Care. Bradley T. Wajda D.O.
Pharmacogenetics in: Primary Care Bradley T. Wajda D.O. Pharmacogenomics Defined Pharmacogenomics uses information about a person s genetic makeup, or genome, to choose the drugs and drug doses that are
More informationINDIVIDUALIZED PATIENT THERAPY: IS IT MORE THAN A BUZZWORD?
INDIVIDUALIZED PATIENT THERAPY: IS IT MORE THAN A BUZZWORD? Kristin Wiisanen Weitzel, PharmD, FAPhA Clinical Associate Professor and Associate Chair, Pharmacotherapy and Translational Research, UF College
More informationKailos Test Results Dr. Ronald McGlennen, Medical Director CLIA#: 01D
Kailos Test Results Dr. Ronald McGlennen, Medical Director ANTIEPILEPTICS Mephenytoin (MESANTOIN ) Phenytoin (DILANTIN ) Valproic Acid (DEPAKOTE, STAVZOR ) ANTIHYPERTENSIVES Atenolol (TENORMIN ) Enalapril
More informationMujeeb U. Shad, M.D., M.S.C.S. Associate Professor of Psychiatry Oregon Health & Science University, Portland Oregon Supervising Psychiatrist Oregon
Mujeeb U. Shad, M.D., M.S.C.S. Associate Professor of Psychiatry Oregon Health & Science University, Portland Oregon Supervising Psychiatrist Oregon State Hospital, Salem Oregon Assurex Health Inc. has
More informationFalk Symposium 156: Genetics in Liver Disease. Pharmacogenetics. Gerd Kullak-Ublick
Falk Symposium 156: Genetics in Liver Disease Pharmacogenetics Gerd Kullak-Ublick Division of Clinical Pharmacology and Toxicology Department of Internal Medicine University Hospital Zurich Freiburg, 8.
More informationKailos Test Results Dr. Ronald McGlennen, Medical Director CLIA#: 01D
PATIENT: Doe, Jane (F) COLLECTED: 10/14/2014 SAMPLE TYPE: Buccal ACCESSION: CL-4194-DM DOB: 1985-01-01 RECEIVED: 12/30/2015 PHYSICIAN: Dr. RONALD C MCGLENNEN PATIENT ID: REPORTED: 12/30/2015 PRACTICE:
More informationCYP2D6: mirtazapine 2001/2002/2003
CYP2D6: mirtazapine 2001/2002/200 Cl or = oral clearance,=c ss = steady state concentration, EM = extensive metaboliser, IM = intermediate metaboliser, MR = metabolic ratio, NS = non-significant, PM =
More informationCytochrome p450 Genotyping
Cytochrome p450 Genotyping Policy Number: Original Effective Date: MM.02.004 04/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/18/2015 Section: Medicine Place(s) of
More informationRight drug. Right dose. Right now. Delivering on the promise and value of personalized prescribing
Right drug. Right dose. Right now. Delivering on the promise and value of personalized prescribing 2 Table of Contents Part One: Pharmacogenetics 101...Slides 4-16 Time Requirement: 20 minutes Part Two:
More informationPharmacogenomics of Antidepressant Medications
Research Reviews: Pharmacy and Pharmaceutical Sciences e-issn: 2320-1215 www.rroij.com Pharmacogenomics of Antidepressant Medications Amanpreet Kooner and Inder Sehgal* California Health Sciences, University
More informationGenomics & Personalized Medicine: Pharmacogenomics
Genomics & Personalized Medicine: Pharmacogenomics Russ B. Altman, MD, PhD Departments of Bioengineering & Genetics PharmGKB, http://www.pharmgkb.org/ Stanford University Outline of comments today Introduction
More informationApplication of Pharmacogenetics Supplementary Worksheet
Application of Pharmacogenetics Supplementary Worksheet Section 1 Health Care Problem Section 2 Drug Metabolism Section 3 Phase I & II metabolism Section 4 Inhibitors and Inducers Section 5 DNA & Drug
More informationCytochrome P450 Drug Interaction Table Flockhart Table
Cytochrome P450 Drug Interaction Table Flockhart Table The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. CYTOCHROME P450 DRUG INTERACTION TABLE A
More information2015 Annual Physician Notice
0 Annual Physician Notice The Office of Inspector General (OIG) recommends clinical laboratories send notices to physicians and other providers who use their services, at least once a year, to inform the
More informationPharmacogenomics: Genetic variations in drug metabolism and utilization. Disclosure
Pharmacogenomics: Genetic variations in drug metabolism and utilization Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC, FNAP President, Fitzgerald Health Education Associates, North Andover,
More informationTo understand the formulary process from the hospital perspective
Formulary Process Michael A. Militello, Pharm.D. Cleveland Clinic Cleveland Clinic 2011 Goal and Objectives To understand the formulary process from the hospital perspective p To list the various panels
More informationJ. David Kinzie, M.D., FAC Psych Professor of Psychiatry
J. David Kinzie, M.D., FAC Psych Professor of Psychiatry I. The Evidence Against Evidence- Based Practice II. The Personal Side of Personal Medicine III. Why Epistemology is Important Example is 42-year-old
More informationGenetic Testing Patient Guide
Genetic Testing Patient Guide Over the last decade, pharmacogenetics has become increasingly significant to clinical practice. Psychiatric patients, in particular, may benefit from pharmacogenetic testing
More informationSAMPLE REPORT. Current Patient Prescriptions. Medical Name Common Name Dosage Time on Medication Ketoconazole Nizoral 400 mg 6 weeks
SAMPLE REPORT Patient: John Smith Patient Information: Patient: John Smith Patient ID: 495 DOB: Jun 09, 1977 Collection Date: Jun 21, 2017 Accession #: 6 Physician: Dr. Dan Erlanger Physician ID: 6 Report
More informationGeneral Discussion 4
General Discussion 4 General Discussion 115 Introduction Psychiatry is considered to be one of the first medical disciplines that will implement pharmacogenetic testing in daily clinical practice. The
More informationAddressing phenoconversion: the Achilles heel of personalized medicine
British Journal of Clinical Pharmacology DOI:10.1111/bcp.12441 Addressing phenoconversion: the Achilles heel of personalized medicine Rashmi R. Shah 1 & Robert L. Smith 2 1 Rashmi Shah Consultancy Ltd,
More informationPharmacogenomics-based individualization of drug therapy
ETH Zurich-JST Workshop on Medical Research, 15 Sep 2008 Pharmacogenomics-based individualization of drug therapy Taisei Mushiroda, Ph.D. Laboratory for Pharmacogenetics Center for Genomic Medicine, RIKEN
More informationMOVING TOWARD GENETIC PROFILING IN PATIENT CARE: THE SCOPE AND RATIONALE OF PHARMACOGENETIC/ECOGENETIC INVESTIGATION
0090-9556/01/2904-580 585$3.00 DRUG METABOLISM AND DISPOSITION Vol. 29, No. 4, Part 2 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 290125/896492 DMD 29:580 585,
More informationPain Medication DNA Insight TM
Pain Medication DNA Insight TM TESTING SUMMARY JULY 2014 AUTHORS Alok Tomar, PhD Adrian Vilalta, PhD Pain Medication DNA Insight TM Precision Medicine and Pharmacogenetics of Pain Medications 1. Introduction
More informationOver the last 50 years, the scientific and medical community has
Precision medicine and pharmacogenomics in community and primary care settings Over the last 50 years, the scientific and medical community has seen the field of pharmacogenomics and precision medicine
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_5_fluorouracil_use_in_cancer_patients 1/1/2019 NA 1/1/2020 1/2019 Policy Effective April
More informationI have NO actual or potential conflicts of interest in relation to this educational presentation.
Genotyping The Patient Requiring Mental Health Medications: When Does It Make Sense? Charles F. Caley, PharmD, BCPP Clinical Professor UConn School of Pharmacy Storrs, CT I have NO actual or potential
More informationTitle of Lecture: Pharmacokinetics II Metabolism and Excretion (Problem 17, Lecture 2, 2009)
Author of Lecture: Hilmer, Sarah (Dr.) Title of Lecture: Pharmacokinetics II Metabolism and Excretion (Problem 17, Lecture 2, 2009) COMMONWEALTH OF AUSTRALIA Copyright Regulations 1969 WARNING This material
More informationETHNICITY AND PSYCHOTROPIC RESPONSE
Ethnic Differences in Drug Metabolism ETHNICITY AND PSYCHOTROPIC RESPONSE Bridging Cultures: Improving Evaluation & Treatment of Cognitive 8 March 28 Keh-Ming Lin, M.D., M.P.H. Professor Emeritus of Psychiatry,
More informationBig Data Course Week 7 Test2Learn TM 5/7/16
The site is http://api.test2learn.com Usernames are first letter of first-name + first 3 letters of last name (i.e. John Smith would be jsmi ) Passwords are the same as the usernames. Everyone will need
More informationPHARMACOGENETICS OF BREAST CANCER
PHARMACOGENETICS OF BREAST CANCER MALGORZATA JAREMKO, PhD Mount Sinai School of Medicine, Department of Genetics and Genomic Sciences Outlines Breast cancer therapeutic situation Pharmacogenetics of antiestrogen
More informationGan GG Department of Medicine University Malaya Medical Centre Kuala Lumpur
Gan GG Department of Medicine University Malaya Medical Centre Kuala Lumpur outline Definitions Genetic polymorphisms and drugs therapy a)warfarin b) Mercaptopurine c) Methotrexate d) Clopidogrel e) others
More informationSAMPLE REPORT MENTAL HEALTH DNA INSIGHT
PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROFESSIONAL Glenn Braunstein.D. 6777 Nancy Ridge Drive San Diego, CA 92121 US LABORATORY INFO ACCESSION NUBER ACTIVATION CODE SPECIEN
More information2/28/2010. Pharmacogenomics and the Asian Population. Limited efficacy/response to drugs already on the market
Pharmacogenomics and the Asian Population Majority are medication related Alan H.B. Wu, Ph.D. Professor, Laboratory Medicine, UCSF Section Chief, Clinical Chemistry, February 27, 20 Limited efficacy/response
More informationPharmacogenetics: From Bench to Byte
Pharmacogenetics: From Bench to Byte 3 JJ Swen, I Wilting, AL de Goede, L Grandia, H Mulder, DJ Touw, A de Boer, JMH Conemans, TCG Egberts, OH Klungel, R Koopmans, J van der Weide, B Wilffert, H-J Guchelaar
More informationComprehensive Drug Information for Smith, John
PATIENT INFORMATION Name: Smith, John DOB: April 22, 1973 Age: 42 Sex: Male SAMPLE Date Collected: March 21, 2016 Date Received: March 21, 2016 Case ID: CARDI16-000001 Source: Buccal Swabs Comprehensive
More informationAsian Journal of Modern and Ayurvedic Medical Science ISSN [ONLINE]
Asian Journal of Modern and Ayurvedic Medical Science ISSN 2279-0772 [ONLINE] Volume: volume2,number 1 publication Date: Tuesday, January 01, 2013 Published by Mpasvo [article url http://www.ajmams.com/viewpaper.aspx?pcode=1ea96e49-1604-434e-96ee-6cc8fd946cbb
More informationGenetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
The Pharmacogenomics Journal (2005) 5, 6 13 & 2005 Nature Publishing Group All rights reserved 1470-269X/05 $30.00 REVIEW Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary
More informationPersonalized Medicine & Treatments
Personalized Medicine & Treatments NASCHIP September 14, 2007 Teresa DeLuca, MD, MBA Vice President Department of Personalized Medicine Medco is a registered trademark of Medco Health Solutions, Inc. Pipeline
More informationTaking the Pain Out of Pain Management Testing
Taking the Pain ut of Pain Management Testing Welcome Taking the Pain ut of Pain Management Testing ctober 5, 2010 Your Host: Karen Riba Handout available by clicking on handout icon, in upper right hand
More informationFarmacologia di genere. Prof. Alberto Corsini Università degli Studi di Milano
Farmacologia di genere Prof. Alberto Corsini Università degli Studi di Milano Women have been less enrolled in clinical trials A gender-specific analysis usually is not included in the evaluation of results
More informationCytochrome p450 Genotyping
Cytochrome p450 Genotyping Policy Number: Original Effective Date: MM.02.004 04/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 09/01/2016 Section: Medicine Place(s) of
More informationPERSONALIZED MEDICINE
Clinical Applications of Pharmacogenomics- Based Medicine in Pediatrics Michael D. Reed, PharmD, FCCP, FCP Director, Rebecca D. Considine Research Institute Division of Clinical Pharmacology & Toxicology
More informationSupplement to: Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC ) for CYP2D6
Supplement to: Pharmacogenetics Implementation Consortium Guideline (CPIC ) for CYP2D6 and CYP2C19 Genotypes and Tricyclic Antidepressants: 2016 Update J. Kevin Hicks 1, Katrin Sangkuhl 2, Jesse J. Swen
More informationSLCO1B1 Pharmacogenetic Competency
SLCO1B1 Pharmacogenetic Competency Updated on 6/2015 Pre-test Question # 1 Which of the following is not currently a recognized SLCO1B1 phenotype? a) Low function b) Normal function c) Intermediate function
More informationGenetic Testing for Pharmacogenetics
Genetic Testing for Pharmacogenetics MP9479 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below (1.0 and 3.0) Additional Information: None Prevea360 Health Plan
More information